Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/STAT2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961531 | Oral cavity | NEOLP | response to virus | 80/2005 | 367/18723 | 3.70e-10 | 3.14e-08 | 80 |
GO:00603373 | Oral cavity | NEOLP | type I interferon signaling pathway | 22/2005 | 50/18723 | 1.82e-09 | 1.18e-07 | 22 |
GO:00713573 | Oral cavity | NEOLP | cellular response to type I interferon | 22/2005 | 52/18723 | 4.49e-09 | 2.54e-07 | 22 |
GO:003434031 | Oral cavity | NEOLP | response to type I interferon | 23/2005 | 58/18723 | 9.04e-09 | 4.55e-07 | 23 |
GO:00019593 | Oral cavity | NEOLP | regulation of cytokine-mediated signaling pathway | 41/2005 | 150/18723 | 1.03e-08 | 5.12e-07 | 41 |
GO:00607593 | Oral cavity | NEOLP | regulation of response to cytokine stimulus | 43/2005 | 162/18723 | 1.19e-08 | 5.70e-07 | 43 |
GO:001922122 | Oral cavity | NEOLP | cytokine-mediated signaling pathway | 88/2005 | 472/18723 | 1.37e-07 | 4.80e-06 | 88 |
GO:005160731 | Oral cavity | NEOLP | defense response to virus | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
GO:014054631 | Oral cavity | NEOLP | defense response to symbiont | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
GO:000283131 | Oral cavity | NEOLP | regulation of response to biotic stimulus | 65/2005 | 327/18723 | 5.93e-07 | 1.74e-05 | 65 |
GO:004343431 | Oral cavity | NEOLP | response to peptide hormone | 76/2005 | 414/18723 | 1.79e-06 | 4.33e-05 | 76 |
GO:00603383 | Oral cavity | NEOLP | regulation of type I interferon-mediated signaling pathway | 13/2005 | 36/18723 | 5.04e-05 | 6.90e-04 | 13 |
GO:00450883 | Oral cavity | NEOLP | regulation of innate immune response | 43/2005 | 218/18723 | 5.49e-05 | 7.44e-04 | 43 |
GO:000268331 | Oral cavity | NEOLP | negative regulation of immune system process | 73/2005 | 434/18723 | 6.18e-05 | 8.22e-04 | 73 |
GO:0001960 | Oral cavity | NEOLP | negative regulation of cytokine-mediated signaling pathway | 20/2005 | 81/18723 | 2.69e-04 | 2.71e-03 | 20 |
GO:005077731 | Oral cavity | NEOLP | negative regulation of immune response | 37/2005 | 194/18723 | 3.52e-04 | 3.38e-03 | 37 |
GO:004582431 | Oral cavity | NEOLP | negative regulation of innate immune response | 18/2005 | 71/18723 | 3.79e-04 | 3.57e-03 | 18 |
GO:00028323 | Oral cavity | NEOLP | negative regulation of response to biotic stimulus | 24/2005 | 108/18723 | 3.87e-04 | 3.63e-03 | 24 |
GO:00607611 | Oral cavity | NEOLP | negative regulation of response to cytokine stimulus | 20/2005 | 86/18723 | 6.22e-04 | 5.33e-03 | 20 |
GO:003134811 | Oral cavity | NEOLP | negative regulation of defense response | 44/2005 | 258/18723 | 1.24e-03 | 9.13e-03 | 44 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa05171310 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAT2 | SNV | Missense_Mutation | rs755127513 | c.2491G>A | p.Glu831Lys | p.E831K | P52630 | protein_coding | deleterious_low_confidence(0.01) | benign(0.303) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
STAT2 | SNV | Missense_Mutation | | c.404N>G | p.Glu135Gly | p.E135G | P52630 | protein_coding | tolerated(0.13) | benign(0.054) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
STAT2 | SNV | Missense_Mutation | | c.2403N>T | p.Glu801Asp | p.E801D | P52630 | protein_coding | tolerated_low_confidence(0.25) | benign(0.007) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.599N>G | p.Gln200Arg | p.Q200R | P52630 | protein_coding | tolerated(0.09) | probably_damaging(0.992) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
STAT2 | SNV | Missense_Mutation | novel | c.2527N>A | p.Asp843Asn | p.D843N | P52630 | protein_coding | deleterious_low_confidence(0) | benign(0.104) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | insertion | In_Frame_Ins | novel | c.1120_1121insAAAGGAACAGGGGTTGGG | p.Arg374delinsGlnArgAsnArgGlyTrpGly | p.R374delinsQRNRGWG | P52630 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
STAT2 | SNV | Missense_Mutation | novel | c.1063G>A | p.Glu355Lys | p.E355K | P52630 | protein_coding | tolerated(0.14) | probably_damaging(0.953) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
STAT2 | SNV | Missense_Mutation | | c.613G>C | p.Glu205Gln | p.E205Q | P52630 | protein_coding | tolerated(0.17) | possibly_damaging(0.889) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.2348N>T | p.Ser783Leu | p.S783L | P52630 | protein_coding | tolerated_low_confidence(0.25) | benign(0.003) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.2309N>C | p.Val770Ala | p.V770A | P52630 | protein_coding | tolerated_low_confidence(0.81) | benign(0) | TCGA-HM-A3JK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |